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Abstract
Calcium sulfate, a bioresorbable material, has been used as a bone substitute material and antibiotic vehicle. The
increasing porosity of calcium sulfate beads might improve drug delivery capacity as well as enhance the antibiotic elution
property. High porous calcium sulfate (HPCS) beads were fabricated using a salt leaching technique as a new bead type for
antibiotic delivery system. Gentamicin-based antibiotic beads were conducted by impregnating gentamicin (3.8% w/w) with
polymethylmethacrylate (PMMA), or coating of PMMA, native calcium sulfate (NCS), and HPCS with gentamicin solution.
Physical properties, microstructure, and gentamicin elution from gentamicin-impregnated PMMA (GI-PMMA), gentamicin-
coated PMMA (G-PMMA), gentamicin-coated NCS (G-NCS), and gentamicin-coated HPCS (G-HPCS) were compared. The
osteoblast attachment revealed that PMMA, NCS, and HPCS beads were not toxic to h-OBs after co-incubation for seven
days. Furthermore, more h-OBs attachment appeared in HPCS beads compared to PMMA and NCS beads after co-culture for
7 days. Eluted gentamicin from G-NCS and G-HPCS beads were greater than those from GI-PMMA and G-PMMA beads
during the experimental period. All types of beads were able to elute gentamicin for 10 days except G-PMMA, which released
gentamicin only for four days. The highest to lowest total concentrations of eluted gentamicin were from G-NCS, G-HPCS,
G-PMMA, and GI-PMMA, respectively. These results suggested that the HPCS beads improved local antibiotic delivery and
improved h-OBs attachment.
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1. Introduction
Antibiotic impregnated beads have commonly been
used for standard treatment of local infected tissues espe-
cially in osteomyelitis (Roeder et al., 2000; Koo et al., 2001;
Gondusky et al., 2009). Antibiotic-impregnated polymethyl-
methacrylate (PMMA) bone cement has been clinically used
in  various  areas,  including  joint  replacement  surgery  and
osteomyelitis management (Kelsey et al., 1995; Roeder et al.,
2000; Malizos et al., 2010). However, many disadvantages of
PMMA were revealed in osteomyelitis managements, includ-
ing the requirement for surgical removal (Mader et al., 2002;
Nelson et al., 2002), the enhancement of bacterial coloniza-
tion (Mader et al., 2002), the high cost of management, and
the release of toxic substances during setting (Santschi et al.,
2003).  Unlike  PMMA,  antibiotic  delivery  system  using
calcium sulfate may serve as a better antibiotic carrier material
due to its biocompatible and biodegradable properties. The
implanted calcium sulfate beads could be totally resorbed
with minimal inflammation (Thomas et al., 2009). In addition,
the beneficial effects of calcium sulfate on osteoconductive
activity led to use this material in both orthopedic and dental
procedures (Damien et al., 1991).
The porosity of bone substitute material was one of
the most important features of an implanted material affect-
ing new bone regeneration. Micropores allowed a migration
of endothelial cells, promoted a differentiation of osteoblast
and osteoprogenitor cells, encouraged vascularization, and
contributed to osteoblast proliferation and differentiation
(Kusmanto, 2008). The pore size of the material was also a
significant factor for bone regeneration. The minimum pore
size required for bone regeneration was approximately 100
mm (Hulbert et al., 1970). The porosity of the material could
be increased with various techniques, such as leaching of
soluble  particles  (Hou  et  al.,  2003;  Joël  Reignier,  2006;
McLaren et al., 2007), mechanical and chemical techniques
(Frame, 1975; Shiramizu et al., 2008). The leaching of soluble
particles technique was an effective method to control the
amount and size of pore, which allowed the measurement of
quantity and size of the particles (Hou et al., 2003). Various
antibiotics were used to co-operate with antibiotic beads,
including aminoglycosides, -lactam agents, and quinolones
(Nandi, 2009). Gentamicin was frequently used in antibiotic-
releasing beads since it has broad-spectrum antimicrobial
activity and high solubility. It resisted to a high temperature
during the PMMA and calcium sulfate dihydrate settings
(Wahlig et al., 1980). In our study, high porous calcium sulfate
(HPCS) beads were developed by a salt leaching method and
were studied in vitro for antibiotic releasing compared with
native calcium sulfate (NCS) and PMMA beads. We hypo-
thesized that HPCS beads could enhance a higher eluted
gentamicin concentration than NCS and PMMA beads in an
initial phase with sufficient eluted concentration in sustain
phase and could be compatible with human osteoblast.
The  purposes  of  this  study  were  to  compare  the
physical properties, elution characteristics of gentamicin
released from gentamicin-impregnated PMMA beads (GI-
PMMA),  gentamicin-coated  PMMA  beads  (G-PMMA),
gentamicin-coated native calcium sulfate beads (G-NCS) and
gentamicin-coated high porous calcium sulfate beads (G-
HPCS),  together  with  the  human  osteoblast  attachment
among PMMA, NCS, and HPCS beads.
2. Material and Methods
2.1 Bead preparation
The PMMA and calcium sulfate beads were catego-
rized for elution test into four groups: gentamicin impreg-
nated PMMA beads (GI-PMMA), gentamicin coated PMMA
beads (G-PMMA), gentamicin coated native calcium sulfate
beads (G-NCS), and gentamicin coated high porous calcium
sulfate beads (G-HPCS).
Preparation  of  GI-PMMA  beads:  GENTAFIX3
(TEKNIMED S.A., France) consisted of 3.8% w/w gentamicin
in polymethymethacrylate base. The bone cement powder
was  mixed  with  a  liquid  monomer  according  to  company
recommendation.  The  mixture  was  poured  into  the  mold
(diameter 5 mm, height 4 mm). For the complete polymeriza-
tion, the PMMA was solidified at room temperature for 3
hours.
Preparation   of   G-PMMA   beads:  CEMFIX3
(TEKNIMED  S.A.,  France)  was  a  polymethymethacrylate
bone cement without antibiotics. The PMMA was prepared
according to company recommendation. After complete poly-
merization of PMMA, CEMFIX3
 pellets were immersed in
gentamicin solution, 40 mg ml
-1, (T.P.drug laboratory, Thai-
land) for three hours, and then were dried under an air blower.
Preparation of G-NCS beads: Calcium sulfate hemi-
hydrate (CaSO4 ½ H2O) (Sigma, U.S.A.) was used to prepare
calcium  sulfate  beads.  Ten  grams  of  calcium  sulfate  hemi-
hydrates were mixed with 7 ml distilled water. The homo-
genous mixture was poured into the mold (diameter 5 mm,
height  4  mm)  and  the  beads  were  set  overnight  at  room
temperature. After the settlement of calcium sulfate beads
were achieved, these beads were submerged in gentamicin
solution, 40 mg ml
-1, (T.P.drug laboratory, Thailand) for three
hours, and then were dried under the blower.
Preparation of G-HPCS beads: Ten grams of calcium
sulfate hemihydrates (Sigma, U.S.A.) were mixed with 10 g
sodium chloride (Sigma, USA) and 7 ml distilled water. The
homogenous  mixture  was  poured  into  the  mold  until  the
beads set as G-NCS. Sodium chloride was leached out of the
calcium sulfate beads by using deionized water in an ultra-
sonic  cleaner  (JAC  ultrasonic  4020P,  KODO  Technical
Research Co. Ltd; Gyeonggi-Do, South Korea) for 30 minutes,
with five times of repetition, then the calcium sulfate beads
were  dried  overnight  at  40°C.  The  calcium  sulfate  beads,
subsequently, were immersed in gentamicin sulfate solution,
40 mg ml
-1, (T.P.drug laboratory, Thailand) for three hours
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2.2 Physical properties of antibiotic beads
Physical properties of GI-PMMA, G-PMMA, G-NCS,
and G-HPCS beads were determined in aspect of weight (mg),
total porosity (%), water uptake (%), and mass loss (%). The
determination  of  total  porosity  of  gentamicin  beads  was
performed according to the Archimedes’s principle of mass
displacement (Jones, 1993; Bruckschen, 2005). Water uptake
capacity of gentamicin beads was undertaken by weighing
the gentamicin beads before and after the immersion in water
(Baro et al., 2002). In addition, mass loss level was weighed
before  and  after  the  gentamicin  beads  were  bathed  in
phosphate buffer saline (PBS) (Sigma, U.S.A.) for 10 days
(Baro et al., 2002).
2.3 Human’s osteoblast attachment
Osteogenic compatibility of PMMA, NCS and HPCS
beads were compared by using human’s osteoblasts (h-OBs)
which were subcultured from primary human osteoblasts.
Bead materials were loaded with 20 mL of h-OBs 2.510
5
cells cm
-3 in Dulbecco’s Modified Eagle Medium (DMEM)
complete medium (BioWhittaker, Lonza, U.S.A.) and placed
in a 24-well plate. Then, that plate was incubated in CO2 incu-
bator at 37.0±1.0°C, 5.0% CO2, and 95±5% humidity. The
samples were analyzed in the first and the seventh days after
the incubation for testing viability and morphology of cell-
seed specimen.
The cell seed on the bead surface was observed by
scanning electron microscopy (SEM). Samples were prepared
according to standard method for SEM, including fixation,
wash, dehydration by using critical point dryer (Bal-Tec
CPD030, Bal-Tec Union Ltd., Liechtenstein), and gold coat-
ing with gold coater (JEOL JFC-1200, JEOL, Japan). The
attachment  of  osteoblast  on  samples  was  observed  by  a
scanning electron microscope (HITACHI S-3400N, HITACHI,
Japan) on the first and the seventh day after incubation.
2.4 Microstructure investigation
The gentamicin beads in each group were sampled
randomly and analyzed with scanning electron microscope
after drug loading to characterize the microstructure of beads
and antibiotic housing. The beads were coated with gold
(IB-2, Eiko Engineering, Co. Ltd., Japan) and analyzed with
scanning electron microscope (JSM-5600LV, JEOL,  Japan)
operated by 10 kV at ×35, ×100, ×200 and ×500 from a cross-
section and a surface view.
2.5 Determination of gentamicin elution test
Five  beads  in  each  group  were  immersed  in  PBS
(Sigma, U.S.A). Each bead was incubated in 1 ml PBS, pH 7.4,
at  37°C  for  24  hours  in  a  tube.  The  dissolution  PBS  was
collected and 1 ml fresh PBS was added every 24 hour for 10
days through the experimental period. All dissolution samples
were kept at -20°C until analysis and were tested within one
week. Eluted gentamicin concentrations were determined by
microbiological assay using Bacillus subtilis (ATCC 6633)
as an indicator organism (Ficker et al., 1990).
2.6 Statistical analysis
All the analyses were carried out using NCSS 2007
(Kaysville,  UT,  USA).  The  concentration  of  gentamicin
sulfate released from GI-PMMA, G-PMMA, G-NCS, and G-
HPCS beads was analyzed by repeated ANOVA followed by
a Tukey’s multiple comparison test. Physical properties of the
beads in each group were compared with one-way ANOVA
and followed by a Tukey’s multiple comparison test. Data
was expressed as the mean ± standard deviation. Values with
P<0.05 were considered statistical significant.
3. Results
3.1 Antibiotic beads characteristics
Gross appearances of GI-PMMA, G-PMMA, G-NCS
and G-HPCS beads are shown in Figure 1. The GI-PMMA
and G-PMMA beads had no visible pores on the surface,
while  G-NCS  beads  had  a  small  number  of  visible  pores.
Interestingly, G-HPCS beads had numerous visible pores on
the bead surface. Physical properties of gentamicin beads,
including weight (mg), porosity (%), water uptake (%), and
mass loss (%) are shown in Table 1.
3.2 Human’s osteoblast attachment
Since different concentrations of gentamicin were
released from each bead and might has an effect on cellular
growth and proliferation, GI-PMMA, G-PMMA, G-NCS, and
G-HPCS were not used for an osteoblast attachment test.
Three  types  of  bead  materials  (no  antibiotic)  were  used,
Figure 1. Beads are presented in each group in top and side views.
Beads were arranged from left to right in the following
order:  GI-PMMA,  G-PMMA,  G-NCS  and  G-HPCS,
respectively. GI-PMMA and G-PMMA beads had no
visible pores on the surface, while the G-NCS bead has a
few pores on the surface. Numerous visible pores were
found on the surface of G-HPCS bead in both top and
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including PMMA beads, NCS beads and HPCS beads. Scan-
ning electron microscopic images of material surface showed
the intact h-OBs cells with normal morphology and extend-
ing filopodia in which indicated the survival of h-OBs on
PMMA, NCS, and HPCS bead surfaces (Figure 2). Interest-
ingly, scanning electron microscopic pictures displayed that
the h-OBs numbers were significantly increased in HPCS
beads compared with that in NCS beads and in PMMA beads
after cell culture for seven days.
3.3 Microstructure observation
According to observations of GI-PMMA, G-PMMA,
G-NCS, and G-HPCS beads, all had different microstructures.
GI-PMMA and G-PMMA beads had no crystal structures
and fewer pores, while G-NCS and G-HPCS beads had crystal
structures and numerous pores (Figure 3). The surface of GI-
PMMA beads was rougher than G-PMMA beads. The cross
sectional view of GI-PMMA and G-PMMA beads showed
the cracks on the rough surface, but gentamicin particle was
not observed in both groups. Furthermore, fewer holes were
noticed on both surface and the cross-section views in both
GI-PMMA and G-PMMA beads.
The microstructures of G-NCS and G-HPCS beads
were different in terms of porosity and crystal size on both
surface and cross sectional views. The average diameters of
calcium sulfate crystals of G-NCS and G-HPCS beads were
1.15±0.23 mm and 10.42±2.04 mm, respectively, whereas the
average pore sizes of G-NCS and G-HPCS beads were 1.59±
0.31 mm and 22.37±6.48 mm, respectively. Not only in G-
HPCS beads, but also in G-NCS beads macropores were
found. G-HPCS beads consisted of numerous macropores
(average size 385.44±101.97 mm) in both cross sectional and
surface views, while few macropores were found in G-NCS
beads. In addition, both surface and cross sectional views,
the  crystal  structure  of  calcium  sulfate  was  coated  with
Table 1. Physical properties of antibiotic beads, including weight (mg), porosity (%),
water uptake (%) and mass loss (%) of GI-PMMA, G-PMMA, G-NCS, and
G-HPCS beads.
    Group Weight (mg) Porosity (%) Water uptake (%) Mass loss (%)
GI-PMMA 119.38±7.45
a    2.10±2.82
a    8.65±1.88
a 1.50±0.25
a
G-PMMA 117.93±8.36
a    2.89±3.37
a    7.56±3.16
a 0.78±0.47
a
G-NCS 163.08±5.73
b 25.71±5.10
b 27.17±2.42
b 5.73±0.48
b
G-HPCS   84.92±6.38
c 42.32±4.57
c 51.15±4.66
c 9.19±1.52
c
a,b,c Different superscripts within column indicate significant difference (p<0.05).
Figure 2. Human osteoblast (h-OBs) (white arrows) attached to the
surface of PMMA bead (A, D), NCS bead (B, E), and
HPCS (C, F) bead on day 1 and day 7 (magnification
×500).
Figure 3. Scanning  electron  microscope  micrograph  showing  the
microstructure of a gentamicin bead including GI-PMMA
(A, B), G-PMMA (C, D), G-NCS (E, F), and G-HPCS
(G, H). Left column is a surface view. Right column is a
cross-sectional view (magnification = 500).297 C. Thitiyanaporn et al. / Songklanakarin J. Sci. Technol. 35 (3), 293-301, 2013
gentamicin sulfate, while it was not observed in the PMMA
beads.
3.4 Antibiotic dissolution
Elution characteristics of GI-PMMA, G-PMMA, G-
NCS, and G-HPCS beads were significantly different from one
another in terms of concentrations (Table 2). The total amount
of gentamicin released from GI-PMMA and G-PMMA beads
was 716.87±272.72 and 1381.64±486.38 µg ml
-1, respectively,
while that in G-NCS and G-HPCS beads was 5003.45±517.27
and 4901.50±1072.69 µg ml
-1, respectively, during a 10-day
experimental period. Gentamicin sulfate could be detected
only for four days in G-PMMA beads, while GI-PMMA beads
could provide gentamicin sulfate until the end of the experi-
ment, similar to G-NCS and G-HPCS beads. Concentrations of
gentamicin sulfate released from G-HPCS beads were higher
than from GI-PMMA and G-PMMA beads in the first five
days; after that during the next five days they decreased to
the same level as of GI-PMMA beads. The highest concen-
trations of eluted gentamicin from all bead types were shown
on the first day. As it can be seen the percentage of gentami-
cin released from of GI-PMMA, G-PMMA, G-NCS, and G-
HPCS beads is 13.05±7.21%, 95.44±1.07%, 52.36±6.41%, and
81.98±1.65%, respectively (Table 3). The total quantity of
gentamicin sulfate in the eluted solution from GI-PMMA and
G-PMMA beads was significantly lower than that released
from G-NCS and G-HPCS beads (Table 2).
4. Discussion
Physical properties of commercial PMMA (GI-PMMA
and G-PMMA), G-NCS and G-HPCS beads were distinct in
weight, total porosity, water uptake capacity, and mass loss.
PMMA beads (GI-PMMA=119.38±7.45 mg and G-PMMA=
117.93±8.36 mg) were lighter than G-NCS beads (163.08±
5.73 mg). However, the G-HPCS beads were the lightest one
(84.92±6.38 mg) since the salt leach increased its porosity up
to 42.32±4.57%. According to water uptake capacity depend-
ing on total porosity, GI-PMMA and G-PMMA beads had
less such capacity since their total porosity was lower than
that of calcium sulfate beads. For mass loss property, the G-
HPCS beads show the highest percentage (9.19±1.52%) of
mass loss after 10 days of the experiment. Since PMMA beads
are a non-dissolvable material, the mass loss in this study
was from getamicin release. A number of studies reported that
polymers coated on the material were used for facilitating the
release of growth factors (Lee et al., 2010; Choi et al., 2011).
In some studies, antibiotic release was controlled by coated
material with thin polymer layer containing antibiotic (Vasilev
et al., 2011; Osaki et al., 2012). The mass loss of G-HPCS
beads might be reduced by coating the material with polymer;
it might slow down antibiotic release from G-HPCS surface.
Human osteoblasts (h-OBs) could survive in HPCS,
NCS, and PMMA beads when observed with scanning elec-
tron microscope. The present study demonstrated that NCS
and PMMA beads were non-toxic materials to h-OBs. This
was in agreement with the previous study conducted in
mouse’s osteoblast (MC3T3-E1) (Lazary et al., 2007). That
study revealed that MC3T3-E1 could proliferate two-fold in
gypsum when compared with PMMA for the first 24 hours.
Furthermore, they found the alkaline phosphatase activity
and SMAD3 expressions in the gypsum group were higher
than in PMMA group. However, our study showed that the
new type of calcium sulfate beads, HPCS, has a high potential
for  using  as  an  osteoconductive  material  similar  to  NCS
beads, while PMMA beads did not have this property.
The  microbiological  assay  using  Bacillus  subtilis
(ATCC 6633) was an agar diffusion method for estimating the
released antibiotic. The limited gentamicin concentration of
Table 2. Concentrations of gentamicin sulfate (µg ml
-1) released from GI-PMMA, G-PMMA,
G-NCS, and G-HPCS beads during the 10 day-experimental periods.
Concentrations of gentamicin sulfate (µg ml
-1)
Day
GI-PMMA G-PMMA G-NCS G-HPCS
1   571.48±279.88
a 1318.88±465.45
b 2640.54±470.28
c 4016.43±846.03
c
2   66.53±18.07
a   55.38±25.65
a 1058.85±160.67
b   624.56±247.94
b
3 26.69±4.81
a  6.77±1.91
b   852.76±204.23
c 159.05±25.84
d
4 16.28±3.51
a  0.61±0.33
b 238.21±36.87
c    48.03±13.96
d
5  9.55±3.72
a UD 102.87±64.40
c 23.32±7.11
b
6  8.60±1.87
a UD   52.05±15.97
b 12.21±3.35
a
7  6.55±1.82
a UD 27.44±8.22
b   7.34±1.86
a
8  3.83±1.48
a UD 13.99±2.32
b   4.93±1.15
a
9  4.27±1.67
a UD 10.65±2.67
b   2.93±1.03
a
10  3.11±0.75
a UD    6.10±1.43
b  2.70±0.42
a
Total  716.87±272.72
a 1381.64±486.38
a 5003.45±517.27
b 4901.50±1072.69
b
a,b,c,d Different letters within row indicate significant difference within day (p<0.05).
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detection was 0.1 µg ml
-1 in our study. The amount of genta-
micin  released  from  the  beads  each  day  was  calculated
according to this assay. The elution kinetics of gentamicin
from GI-PMMA, G-PMMA, G-NCS and G-HPCS beads was
significantly different. The total amount of gentamicin in G-
PMMA, G-NCS and G-HPCS beads could be quantified by
area under the curve, while the gentamicin amount per bead
in  GI-PMMA  was  calculated  by  percent  concentration  of
gentamicin per weight of the bead. This study found that only
small amounts of gentamicin (16.32±7.22% of total genta-
micin)  could  be  eluted  from  GI-PMMA  during  the  10-day
experiment. This corresponded with the previous report that
only 5-8% of antibiotic in PMMA was released from the
exposed surface during the first week (Wahlig et al., 1980).
In contrast, most of gentamicin (99-100%) could be eluted
from G-PMMA, G-NCS, and G-HPCS beads. These results
were  likely  due  to  the  differences  in  gentamicin  coating
method. The release of gentamicin could be separated into
two phases: initial and sustain phases. This phenomenon was
reported in many previous studies (van de Belt et al., 2000;
Wichelhaus et al., 2001; Hendriks et al., 2004; Udomkusonsri
et  al.,  2010).  Likewise,  the  present  study  found  that  such
phenomenon took place with GI-PMMA, G-PMMA, G-NCS,
and G-HPCS beads. Most of gentamicin was eluted from the
beads  within  the  first  day,  known  as  an  initial  phase  and
followed by a sustain phase until the tenth day in GI-PMMA,
G-NCS, and G-HPCS beads. However, the previous study
found  that  80%  of  gentamicin  was  released  from  G-NCS
beads  within  the  first  day  (Wichelhaus  et  al.,  2001).  This
might be due to the amount of solution used for dissolving
gentamicin from the beads. The previous experiment used 5
ml PBS, while 1 ml of PBS was used in the present study.
One milliliter of PBS might be saturated with gentamicin in
the  first  day  in  our  experiment.  For  G-PMMA  beads,  the
gentamicin could be detected in a short period since PMMA
beads had fewer pores on its surface and did not have inter-
connecting pores. Thus, PMMA could uptake antibiotic only
in a low level when it was already in hardening form, owing
to the porosity of the beads that contributed to the perme-
ability to the bead matrix. G-HPCS beads had higher porosity
than  G-NCS  beads,  resulting  in  the  higher  percentage  of
gentamicin released from G-HPCS beads in the initial phase
than that of G-NCS beads.
Gentamicin could coat only on the surface of the
matrix.  The  elution  characteristic  of  G-PMMA  beads  was
different  from  GI-PMMA  beads.  GI-PMMA  could  release
gentamicin until the end of the experiment, because genta-
micin was added to PMMA prior to be hardened and was
incorporated into the matrix of the materials. Antibiotic selec-
tion was limited for producing PMMA antibiotic beads since
it needed a high temperature for the polymerization (Nandi,
2009). In this study, it was found that the antibiotic was in-
appropriate to be added to PMMA after hardening process.
In addition, gentamicin concentration eluted from GI-PMMA
and G-PMMA beads were lower than that of G-NCS and G-
HPCS beads in the total amount. Our results suggested that
PMMA beads have a lower ability as a local drug-release
agent compared with calcium sulfate beads.
The G-HPCS bead was a new type of calcium sulfate
bead used in the present study. It has high porosity, high
antibiotic up taking and releasing. Furthermore, the HPCS
bead is non-toxic to h-OBs and provided a positive effect on
h-OBs attachment. G-HPCS and G-NCS beads could provide
high  concentration  of  gentamicin  during  the  experiment.
Although  G-NCS  beads  could  provide  higher  amount  of
gentamicin than G-HPCS beads after the second day through
the end of study, the concentration of gentamicin released
from G-HPCS was not difference from GI-PMMA until the
Table 3. Percentage of gentamicin release in each day from GI-PMMA, G-PMMA,
G-NCS, and G-HPCS beads.
Day GI-PMMA G-PMMA G-NCS G-HPCS
1 13.05±7.21
a 95.44±1.07
b 52.36±6.41
c 81.98±1.65
d
2 1.49±0.42
a 3.99±1.03
a 21.19±3.44
b 12.27±2.91
b
3 0.60±0.15
a 0.52±0.15
a 16.86±3.40
b 3.46±1.30
a
4 0.36±0.07
ab 0.05±0.02
a 4.74±0.66
c 1.02±0.36
b
5 0.22±0.10
a UD 2.08±1.42
b 0.49±0.17
a
6 0.19±0.05
a UD 1.05±0.38
b 0.26±0.10
a
7 0.15±0.05
a UD 0.55±0.19
b 0.15±0.05
a
8 0.09±0.04
a UD 0.28±0.07
b 0.10±0.04
a
9 0.09±0.04
a UD 0.21±0.06
b 0.06±0.02
a
10 0.07±0.02
a UD 0.12±0.04
b 0.06±0.02
a
% total release 16.32±7.22
a 100±0.00
b 99.44±0.22
b 99.86±0.04
b
Total (mg/bead) 4.48±0.31
a 1.38±0.49
b 5.03±0.52
a 4.91±1.07
a
a,b,c,d Different letters within row indicate significant difference within day (p<0.05).
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end of the study. These concentrations were above minimal
inhibition  concentration  (MIC)  for  pathogenic  bacteria,
Staphylococcus aureus, which normally caused osteomyeli-
tis exhibiting an MIC90 value (antibiotic concentration that
inhibited the growth of susceptible strain S. aureus by 90%)
of 1 mg ml
-1 for gentamicin in susceptible strains (Fluit et al.,
2000). From these reasons, the G-HPCS beads could be as
applied as a local antibiotic delivery vehicle. Comparing the
elution characteristics between G-NCS and G-HPCS beads,
it was found that the concentration of gentamicin released
from G-HPCS beads in the first day was higher than from G-
NCS beads and then rapidly decreased on the following day.
This result was a consequence of the difference in porosity
level and water uptake capacity of the beads in each group,
leading to a faster dissolution of gentamicin from G-HPCS
than from G-NCS.
This result was similar to a previous study, which
showed the difference of gentamicin and vancomycin releases
from  nanocrystalline  hydroxyapatite  and  calcium  sulfate
beads  (Rauschmann  et  al.,  2005).  The  nanocrystalline
hydroxyapatite in combination with calcium sulfate exhibited
a  higher  porosity  and  water  uptake  capacity  than  a  pure
calcium sulfate. These properties led to a higher antibiotic
uptake  and  faster  release  of  gentamicin  and  vancomycin
within the first day by the composite material (Rauschmann
et al., 2005). The results of our study also correlated with a
previous  study  regarding  the  different  phases  of  surface
roughness, porosity, and wettability of gentamicin-loaded
bone cements (van de Belt et al., 2000). They concluded that
the releasing kinetics of gentamicin from bone cements was
controlled by a combination of surface roughness and poro-
sity. Interestingly, many previous studies showed the dis-
advantage  of  calcium  sulfate  as  it  might  cause  a  transient
cytotoxic  effect,  which  lead  to  inflammatory  reactions
(Coetzee,  1980;  Robinson  et  al.,  1999;  Lee  et  al.,  2002).
Calcium sulfate may cause more acidic microenvironment
followed by a local inflammation at the site of implantation in
human bone (Coetzee, 1980). From this reason, the G-HPCS
bead  has  an  advantage  over  the  G-NCS  bead  since  the
amount of calcium sulfate per bead of G-HPCS was signifi-
cantly lower than for G-NCS beads. An application of G-
HPCS beads could reduce the side effects of calcium sulfate
when implanted in the tissue.
The present study introduced a practical technique to
apply a new type of calcium sulfate bead as local antibiotic
delivery vehicle. The G-HPCS beads eluted higher concen-
tration of gentamicin than GI-PMMA and G-PMMA beads.
Moreover,  G-HPCS  beads  are  cheaper  than  PMMA  beads
and are easier to prepare with gentamicin sulfate in a clinical
setting. Furthermore, gentamicin sulfate could be added to
calcium  sulfate  beads  after  the  hardening  procedure.  The
advantages of dipping antibiotic in post-hardening calcium
sulfate beads included the facilitation of individualized anti-
biotic therapy and the prevention of antibiotic degradation
owing  to  the  sterilization  process  or  thermal  instability
(Dacquet et al., 1992).
5. Conclusion
The release characteristics of gentamicin G-HPCS,
in the present study, could be compared with GI-PMMA, G-
PMMA and G-NCS over ten days. The release of gentamicin
from G-HPCS beads was greater than that from GI-PMMA
and G-PMMA beads. The present study also demonstrated
that  the  concentration  of  gentamicin  from  G-HPCS  and
G-NCS beads was higher than from GI-PMMA and G-PMMA
beads in each day, except for the last five days, where the
gentamicin concentration from G-HPCS and GI-PMMA was
equal.  In  addition,  G-HPCS  beads  in  this  study  not  only
improved local antibiotic delivery, but they also had positive
effects on osteoblast attachment, which was essential for
new bone regeneration in osteomyelitis condition.
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